- Visby Medical recently announced that it raised over $100 million in Series E funding. These are the details.
Visby Medical — a leading medical diagnostic company — recently announced that it has raised over $100 million in its Series E financing round with investment led by Ping An Voyager Partners and joined by the Healthcare of Ontario Pension Plan (HOOPP). This funding round also included participation by existing investors including John Doerr, Cedars Sinai Medical Center, ND Capital, Artiman Ventures, Pitango Venture Capital, Blue Water Life Science Advisors and Nissim Capital.
This funding will enable Visby Medical to scale production capacity from tens to hundreds of thousands of tests per month, further expand the product menu to include COVID + influenza A/B combination testing, antimicrobial resistance panels, and deliver the power of PCR diagnostics to consumers at-home.
KEY QUOTES:
“We’re delighted to be joining Visby Medical at this point in their journey. At Ping An, we have a strong view that telemedicine is here to stay, but will remain limited in scope without dramatic improvements in remote diagnosis capabilities. Visby’s vision of ‘healthcare anywhere’ – combining telemedicine with an easy-to-use, instrument free and high-quality diagnosis tool – is exceptionally compelling.”
— Donald Lacey, Chief Investment Officer at Ping An Voyager Partners
“Visby Medical delivers innovative technology that addresses a critical and growing global need, led by a management team that is forward-thinking and disciplined. HOOPP is pleased to participate in this investment as we expect it will deliver long-term value for the pensions of our members, the healthcare workers of Ontario.”
— Jennifer Shum, AVP, Derivatives and Fixed Income, HOOPP
“When we started Visby Medical in 2012, we set out to revolutionize patient care with fast PCR diagnostics, available to anyone, anywhere at any time. We’ve taken the first steps to deliver on that promise with the world’s first handheld, instrument-free, single-use PCR tests for bacterial and parasitic infections with our Sexual Health Click Test, and for viral infections with our COVID-19 test. We are thrilled to have incredible investors who believe in our vision. This investment signals that experienced healthcare investors recognize the potential that our patented ‘gold standard’ PCR diagnostic technology has in multiple therapeutic areas.”
— Visby Medical Founder and CEO Adam de la Zerda, PhD
